Search Within

Thoracic Oncology

Formats
  1. Meeting Abstract (1709)
  2. Journal Article (1439)
  3. Review (82)
  4. Editorial (58)
  5. Book Section (35)
  6. Guidelines (25)
  7. Conference Paper (21)
  8. Correspondence (10)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3394)
  2. Solid Tumor Oncology Division (3394)
  3. GSK Faculty (1071)
  4. Department of Pathology and Laboratory Medicine (809)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (662)
  6. Human Oncology and Pathogenesis Program (635)

More Groups

People
  1. Mark Kris (872)
  2. Alexander Drilon (637)
  3. Gregory Riely (605)
  4. Charles Rudin (495)
  5. Marc Ladanyi (418)
  6. Matthew Hellmann (412)

More People

Years
  1. 2025 (114)
  2. 2024 (271)
  3. 2023 (273)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (703)
  2. Journal of Thoracic Oncology (517)
  3. Annals of Oncology (278)
  4. Clinical Cancer Research (158)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (89)

More Publications

Publishers
  1. American Society of Clinical Oncology (782)
  2. Elsevier Inc. (738)
  3. American Association for Cancer Research (386)
  4. Oxford University Press (352)
  5. Nature Publishing Group (156)
  6. Elsevier Science, Inc. (79)

More Publishers

Results (3394)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas
    Journal Article

    Johnson, M. L.; Sima, C. S.; Chaft, J.; Paik, P. K.; Pao, W.; Kris, M. G.; Ladanyi, M.; Riely, G. J.
    Cancer (2013)

    Fulltext@MSK | Save
  • Local therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors
    Meeting Abstract

    Yu, H. A.; Sima, C. S.; Drilon, A. E. D.; Varghese, A. M.; Pietanza, M. C.; Azzoli, C. G.; Rizvi, N. A.; Krug, L. M.; Kris, M. G.; Miller, V. A.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Clinical characteristics of patients with malignant pleural mesothelioma (MPM) harboring somatic BAP1 mutations
    Meeting Abstract

    Zauderer, M. G.; Bott, M. J.; McMillan, R.; Sima, C. S.; Rusch, V. W.; Krug, L. M.; Ladanyi, M.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Comparison of the KRAS/EGFR mutation profile and survival of "collegiate smokers" and never smokers with advanced lung cancers
    Meeting Abstract

    Varghese, A. M.; Sima, C. S.; Chaft, J. E.; Johnson, M. L.; Janjigian, Y. Y.; Drilon, A. E. D.; Yu, H. A.; Riely, G. J.; Ladanyi, M.; Kris, M. G.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • ALK and MET genes in advanced lung adenocarcinomas: The Lung Cancer Mutation Consortium experience
    Meeting Abstract

    Varella-Garcia, M.; Berry, L. D.; Su, P. F.; Franklin, W. A.; Iafrate, A. J.; Ladanyi, M.; Camidge, D. R.; Garon, E. B.; Haura, E. B.; Horn, L.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • KIF5B-RET: Discovery of a novel fusion oncogene in lung adenocarcinomas by a systematic screen for tyrosine kinase fusions and identification of patients for a RET targeted therapy trial
    Meeting Abstract

    Suehara, Y.; Arcila, M. E.; Drilon, A. E. D.; Ito, T.; Wang, L.; Hasanovic, A.; Khanin, R.; Rizvi, N. A.; Ladanyi, M.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK-positive (ALK plus ) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ)
    Meeting Abstract

    Scagliotti, G.; Kim, D. W.; Shaw, A. T.; Ou, S. H. I.; Riely, G. J.; Gettinger, S. N.; Besse, B.; Thomas, M.; Salgia, R.; Wilner, K. D.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations
    Meeting Abstract

    Riely, G. J.; Brahmer, J. R.; Planchard, D.; Crino, L.; Doebele, R. C.; Lopez, L. A. M.; Gettinger, S. N.; Schumann, C.; Li, X.; Atkins, B. M.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase II study of cixutumumab (IMC-A12) in thymic malignancies
    Meeting Abstract

    Rajan, A.; Riely, G. J.; Carter, C. A.; Thomas, A.; Khozin, S.; Bergagnini, I.; Berman, A. W.; Scepura, B.; Szabo, E.; Lee, M. J.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Clinical characteristics of ALK plus NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management
    Meeting Abstract

    Otterson, G. A.; Riely, G. J.; Shaw, A. T.; Crino, L.; Kim, D. W.; Martins, R.; Salgia, R.; Zhou, C.; Solomon, B. J.; Wilner, K. D.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save